These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24262439)

  • 41. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?
    Iorfida M; Dellapasqua S; Bagnardi V; Cardillo A; Rotmensz N; Mastropasqua MG; Bottiglieri L; Goldhirsch A; Viale G; Colleoni M
    Ann Oncol; 2012 May; 23(5):1371-1372. PubMed ID: 22412042
    [No Abstract]   [Full Text] [Related]  

  • 43. Trastuzumab beyond progression in HER2-positive metastatic breast cancer.
    Al-Naqqash M; Jasim Al-Serarati W; Farooq Kareem T
    Breast J; 2021 Mar; 27(3):297-299. PubMed ID: 33472271
    [No Abstract]   [Full Text] [Related]  

  • 44. Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers.
    Ahmad A
    Adv Exp Med Biol; 2019; 1152():217-228. PubMed ID: 31456185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In brief: Phesgo - a fixed-dose combination for HER-2 positive breast cancer.
    Med Lett Drugs Ther; 2021 Mar; 63(1619):e43-e44. PubMed ID: 33755658
    [No Abstract]   [Full Text] [Related]  

  • 47. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
    Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
    Ellis MJ
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
    [No Abstract]   [Full Text] [Related]  

  • 50. Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
    Molina-Garrido MJ; Guillen-Ponce C; Mora-Rufete A
    Anticancer Agents Med Chem; 2014 Jun; 14(5):639-45. PubMed ID: 23438846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.
    Sendur MA; Aksoy S; Altundag K
    Future Oncol; 2015; 11(1):13-5. PubMed ID: 25572781
    [No Abstract]   [Full Text] [Related]  

  • 52. HER2/neu in the management of invasive breast cancer.
    Meric F; Hung MC; Hortobagyi GN; Hunt KK
    J Am Coll Surg; 2002 Apr; 194(4):488-501. PubMed ID: 11949754
    [No Abstract]   [Full Text] [Related]  

  • 53. [The requirements to clinicopathology about targeted therapy for breast cancer].
    Jiang ZF; Shen G
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
    [No Abstract]   [Full Text] [Related]  

  • 54. Continuing trastuzumab beyond progression.
    Jahanzeb M
    J Clin Oncol; 2009 Apr; 27(12):1935-7. PubMed ID: 19289613
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A systematic review of the economic evaluations of trastuzumab in metastatic breast cancer.
    Petrou P
    Breast J; 2020 Sep; 26(9):1903-1905. PubMed ID: 32383220
    [No Abstract]   [Full Text] [Related]  

  • 57. Trastuzumab treatment beyond brain progression in HER2- positive metastatic breast cancer.
    Kilickap S; Arslan C
    Ann Oncol; 2009 Jan; 20(1):192. PubMed ID: 19172706
    [No Abstract]   [Full Text] [Related]  

  • 58. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 59. Current status of antibody therapy for breast cancer.
    Toi M; Takada M; Bando H; Toyama K; Yamashiro H; Horiguchi S; Saji S
    Breast Cancer; 2004; 11(1):10-4. PubMed ID: 14718785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER2 inhibition: from discovery to clinical practice.
    Chang JC
    Clin Cancer Res; 2007 Jan; 13(1):1-3. PubMed ID: 17200331
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.